Header Logo

Connection

Mark Olsen to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Mark Olsen has written about Dose-Response Relationship, Drug.
Mark Olsen
Connection Strength
0.022
Dose-Response Relationship, Drug
  1. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012 Apr 20; 30(12):1371-7.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.